PharmaTher Holdings Ltd. (PHRM.CN)
| Previous Close | 0.1250 |
| Open | 0.1200 |
| Bid | 0.1200 x N/A |
| Ask | 0.1250 x N/A |
| Day's Range | 0.1200 - 0.1250 |
| 52 Week Range | 0.1000 - 0.7200 |
| Volume | |
| Avg. Volume | 99,746 |
| Market Cap | 10.94M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0530 |
| Earnings Date | Oct 27, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products for anesthesia and procedural sedation in 2023 TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRR
- GlobeNewswire
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41% at 3-month (p=0.011) post-ketaminePlanning a Phase 3 clinical study to allow for FDA approval of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE
- GlobeNewswire
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
Figure 1 Figure 1: Actual prototype of KETARX™ Ketamine Patch Figure 2 Blood levels of ketamine delivery with KETARX™ ketamine patch relative to time with either a 5 cm2 or 10 cm2 patch KETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous administration Initiating clinical studies by the end of Q4-2022 to suppor
